

# JOINT TRAUMA SYSTEM CLINICAL PRACTICE GUIDELINE (JTS CPG)



## Acute Respiratory Failure (CPG ID: 06)

This CPG describes the associated risk factors, diagnosis, and management of Acute Respiratory Distress Syndrome (ARDS) in combat casualties in the forward deployed environment and the resources available for safe Aeromedical transport of these patients.

### Contributors

LtCol Jeremy Cannon, USAF, MC  
 LTC Jeremy Pamplin, MC, USA  
 LtCol David Zonies, USAF, MC  
 LtCol Phillip Mason, USAF, MC  
 MAJ Christy Sine, USAF, MC  
 COL (ret) Leopoldo Cancio, MC, USA  
 Col Jeffrey McNeill, USAF, MC

LTC Christopher Colombo, MC, USA  
 LTC Erik Osborn, MC, USA  
 CAPT Robert Ricca, MC, USN  
 Patrick Allan, MD  
 MAJ Jeff DellaVolpe, USAF, MC  
 LTC Kevin Chung, MC, USA  
 CAPT Zsolt Stockinger, MC, USN

First Publication Date: 16 Apr 2014

Publication Date: 23 Jan 2017

Supersedes CPG dated: 16 Apr 2014

## TABLE OF CONTENTS

Background .....	2
Definitions .....	2
Diagnosis .....	3
Management .....	3
Ventilator and Gas Exchange Management .....	4
Neuromuscular Blockade .....	5
Prone Positioning .....	5
Fluid Management .....	5
Blood Product Transfusions .....	5
Corticosteroid Administration .....	6
Nutrition and Venous Thromboembolism Prophylaxis .....	6
Sedation Management and Physical Therapy .....	6
ARDS in Pediatric Patients .....	6
Transport of ARDS Patients .....	6
Critical Care Air Transport Team (CCATT) Capabilities .....	6
Advanced Critical Care Evacuation Team (ACCET) Capabilities .....	7
Outcomes .....	8
Performance Improvement (PI) Monitoring .....	8
Population of Interest .....	8
Intent (Expected Outcomes) .....	8
Performance/Adherence Metrics .....	8
System Reporting & Frequency .....	8
Responsibilities .....	9
References .....	9
Appendix A: Diagnosis and Management of ARDS .....	13
Appendix B: ARDSNET Ventilator Management for Patients with ARDS .....	14
Appendix C: Prone Positioning in Patients with ARDS .....	15
Appendix D: Additional Information Regarding Off-label Uses in CPGs .....	16

---

## BACKGROUND

---

Patients with multiple injuries are known to develop lung injury<sup>1</sup> which can result in long-term disability or even death.<sup>2</sup> A recent review of combat casualty deaths following admission to a hospital demonstrated that 8% of potentially preventable deaths are from multi-organ failure which includes ARDS.<sup>3</sup> The purpose of this guideline is to review the diagnostic criteria for ARDS, to describe the frequency of this problem in combat casualties, and to recommend a series of management strategies to permit safe aeromedical evacuation of these patients.

Respiratory failure has been observed in combat casualties for over a century. Some degree of ARDS occurs in between 26% and 33% of combat casualties.<sup>1,4,5</sup> In a review of the DoD Trauma Registry (DoDTR), 152 patients with ARDS were identified over a 7 year period.<sup>6</sup> Independent risk factors for ARDS included female gender, shock or tachycardia on presentation, and severe injury (Military Injury Severity Score (mISS)  $\geq 25$ ). Patients with ARDS had a significantly increased risk of death as compared to intubated controls (12.8% vs. 5.9%, Odds Ratio 1.99, 95% confidence interval [1.12, 3.52],  $p=0.02$ ). Further analysis of this population identified that increased crystalloid infusion and Fresh Frozen Plasma (FFP) transfusion independently predicted ARDS.<sup>7</sup>

---

## DEFINITIONS

---

- ARDS develops as a result of both direct and indirect injury to the lungs. Common causes of ARDS following a direct injury include pneumonia or gastric aspiration. In combat casualties, direct insults such as pulmonary contusion, inhalation injury, and fat emboli may lead to ARDS. ARDS from indirect lung injury can occur in patients who receive multiple transfusions, who develop septic shock, or in those with severe acute pancreatitis.
- Cardiac failure or fluid overload must be ruled out when considering the diagnosis of ARDS. Several other disease processes can also mimic ARDS. Patients with these conditions will benefit from lung-protective ventilator management but may require disease-specific interventions as well. Examples include Acute Eosinophilic Pneumonia (AEP), Acute Interstitial Pneumonitis (AIP), Bronchiolitis Obliterans Organizing Pneumonia (BOOP), and Diffuse Alveolar Hemorrhage (DAH).<sup>8</sup>
- The definition of ARDS was updated in 2012. The new Berlin definition of ARDS reflects a range of severity from mild to moderate to severe, defines “acute onset” as within one week and specifies the need for Positive End Expiratory Pressure (PEEP)  $\geq 5$  cm H<sub>2</sub>O.<sup>9</sup> The original American-European Consensus Conference (AECC) definition of ARDS which also included Acute Lung Injury (ALI)<sup>10</sup> is less practical; so this CPG will refer to the new Berlin definition. Timing of ARDS must occur within one week of a known clinical insult described above, or must be in the context of new or worsening respiratory symptoms. On chest imaging (CXR or CT scan), bilateral opacities must be present which are not fully explained by pulmonary edema, effusions/hemothorax, lobar collapse, or pulmonary nodules. If the above criteria are met, the degree of hypoxemia with a PEEP or Continuous Positive Airway Pressure (CPAP) of at least 5 cm H<sub>2</sub>O determines the severity of ARDS.
  1. **Mild ARDS** = PaO<sub>2</sub> to FiO<sub>2</sub> ratio (P:F) of  $> 200$  and  $\leq 300$ .
  2. **Moderate ARDS** = P:F of  $>100$  and  $\leq 200$ .
  3. **Severe ARDS** = P:F of  $\leq 100$ .
- The diagnosis of ARDS is typically made in patients who have respiratory failure that requires intubation and mechanical ventilation.

---

## DIAGNOSIS

---

Patients suspected of having ARDS on the basis of CXR findings and ventilator settings should have their diagnosis confirmed by following the below guidance.

1. Verify that the patient is likely to have respiratory failure from either a direct or indirect pulmonary injury or the need for mechanical ventilation support.
2. Consider diagnoses which can mimic ARDS as described above.
3. Obtain a good quality anteroposterior upright CXR and look for diffuse infiltrates. Consider a chest CT if this imaging modality is available and the patient is stable for transport to CT.
4. If cardiogenic pulmonary edema and/or fluid overload cannot be fully excluded as the cause of or a contributing factor to the patient's respiratory failure, consider placing a central venous pressure catheter and obtain a trans-thoracic echocardiogram if possible.<sup>11,12</sup>
5. Place the patient on volume- or pressure-control ventilation.
  - a. Tidal volume ( $V_T$ ) approximately 6-8 mL/kg using Predicted Body Weight (PBW), see ARDSNet Card in [Appendix B](#) targeting a plateau pressure ( $P_{PLAT}$ )  $\leq$  30 cm H<sub>2</sub>O or if using a pressure control mode of ventilation, set the inspiratory pressure to 30-35 cm H<sub>2</sub>O and then decrease it gradually to achieve a  $V_T$  of 6-8 mL/kg.
  - b. Set the respiratory rate between 6 and 35 and adjust to achieve a pH  $\geq$  7.3.
  - c. Set PEEP (minimum 5 cm H<sub>2</sub>O) and FiO<sub>2</sub> according to the ARDSNet table<sup>23</sup> to achieve a SpO<sub>2</sub> of 88-95% (PaO<sub>2</sub> of 55-80 mmHg). Allow the patient's gas exchange to equilibrate for 30 minutes and then draw an ABG to calculate the patient's P:F ratio.

If ARDS is confirmed, document the grade (mild, moderate, severe) in the patient's record with the diagnostic criteria used. A recent study further demonstrated that Age-Adjusted Oxygenation Index (AOI) accurately predicts prognosis in patients with ARDS.<sup>13</sup> Traditionally, the Oxygenation Index (OI) is calculated as where MAP is mean airway pressure. This study relied on the ARDSNet database which recorded  $P_{PLAT}$  rather than MAP; so the AOI was calculated as  $(\frac{100 \times P_{PLAT}}{P:F}) + Age$ . These authors found that an AOI of 80-99 in the first four days of ARDS was associated with 50% mortality.

Pediatric trauma patients are also at risk for development of ARDS.<sup>14</sup> While there are many similarities in the pathophysiology of ARDS in adults and children, recent literature has supported a slightly different approach with the diagnostic criteria used in pediatric ARDS.<sup>15,16</sup> Similar to the Berlin criteria for adults, ARDS in children requires respiratory failure not explained by cardiac failure or volume overload. However, instead of utilization of a P:F ratio, recent recommendations have been made to utilize OI to grade severity of ARDS in the pediatric population. As above, OI can be calculated as  $(\frac{100 \times MAP}{P:F})$ . Mild ARDS can be defined as an OI of 4 to <8, moderate ARDS defined as an OI of 8 to <16 and severe ARDS defined as an OI  $\geq$  16.<sup>15,16</sup>

---

## MANAGEMENT

---

The management of patients with ARDS should safely support gas exchange without further injuring the patient's lungs.<sup>17</sup> In fact, using a lung-protective ventilator strategy in *all* intubated patients appears to improve clinical outcomes.<sup>18-20</sup> Providers must also recognize that there are also some limitations imposed by the transport ventilators and that the patient's PaO<sub>2</sub> will always decrease during aeromedical transport.<sup>21,22</sup>

In patients with ARDS, the goal is to limit barotrauma ( $P_{PLAT} \leq 30$  cm H<sub>2</sub>O or peak inspiratory pressure,  $PIP \leq 35$  cm H<sub>2</sub>O if PPLAT cannot be measured), volutrauma ( $V_T$  6-8 mL/kg PBW) and atelectrauma (moderate to high PEEP).<sup>17</sup> Goals should include an  $SpO_2 \geq 88-95\%$  and a  $pH \geq 7.3$  (in traumatic brain injury, this pH goal should be met with the  $PaCO_2$  maintained at 35-40 mm Hg).

Early consultation with an intensivist is encouraged for all patients with moderate to severe ARDS. Military physician-to-physician consultation can be obtained by contacting Landstuhl Regional Medical Center (LRMC) at DSN 314-486-7141 or San Antonio Military Medical Center (SAMMC) at DSN 312-429-BURN (2876).

For Role 3 patient management, see [Appendix A](#).

## VENTILATOR AND GAS EXCHANGE MANAGEMENT

### Lung-Protective Ventilation Settings

Once ARDS has been diagnosed, the patient should be placed on lung-protective ventilation settings according to the ARDSNet ventilator management card.<sup>23</sup> The patient's PBW is determined by measuring the patient's height and then using the appropriate gender-based calculation. Note there are two different PEEP tables, one with a lower PEEP and higher  $FiO_2$  and the other with a higher PEEP and lower  $FiO_2$ . Either is acceptable, but meta-analysis suggests a trend towards improved survival using the high PEEP table in patients with moderate to severe ARDS by modern criteria.<sup>24</sup> In all cases, the "driving pressure" ( $P_{PLAT} - PEEP$ ) should be minimized to optimize the patient's chances of survival.<sup>25</sup> During the initial management, a  $V_T$  of 8 mL/kg may be used, but this should be decreased to 6 mL/kg within 2-4 hours. If the  $P_{PLAT}$  remains above 30 cm H<sub>2</sub>O, the tidal volume can be further reduced to 4 mL/kg so long as there is evidence of adequate oxygen delivery to peripheral tissues (normal lactate and base deficit).<sup>26</sup> Other modes of ventilation besides volume-assist-control can be used, but this should be at the discretion of an intensivist experienced in the management of ARDS.

### Rescue Oxygenation Therapies

Advanced therapies for ARDS patients are limited in an austere environment. Low-level recruitment maneuvers performed by holding 40 cm H<sub>2</sub>O pressure for 40 seconds can be performed by the patient's provider, but the team should be prepared to manage unstable hemodynamics due to decreased venous return. Other measures such as inhaled Nitric Oxide (iNO) or inhaled prostacyclin (Flolan) are not typically available in Role 3 facilities. Advanced rescue ventilator modes such as inverse ratio ventilation or Airway Pressure Release Ventilation (APRV) should be utilized under the supervision of an experienced intensivist.

### Extracorporeal Life Support

Early consideration for Veno-Venous Extracorporeal Life Support (vvECLS) is vital in patients who are failing attempts at lung-protective ventilation.<sup>27</sup> If gas exchange and perfusion goals are not met after 12 hours of lung-protective ventilation and the patient has been paralyzed and proned, then extracorporeal support should be considered. Additionally, transport of patients who are supported with vvECLS may be safer and easier if an extracorporeal transport team is available. (See *Transport of ARDS patients* below).

Indications for initiating Extracorporeal Membrane Oxygenation (ECMO) for respiratory failure include:

1. P:F ration  $< 100$  or plateau pressures  $> 30$  cm H<sub>2</sub>O despite optimal ventilator management.
2. Respiratory acidosis with  $pCO_2 > 70$  and a  $pH < 7.25$  despite optimal ventilator management.
3. Initiation of ARDS rescue therapies (PEEP  $> 15$ , prone positioning, High Frequency Oscillation (HFOC), iNO, prolonged paralysis)
4. Respiratory failure associated with significant barotrauma needed for ventilator support.

ECMO consultation is available 24 hours a day and can be coordinated through the Institute of Surgical Research (ISR) Burn Unit (210-222-BURN). Due to the dramatic sequelae of acute respiratory failure and the time required to generate a potential ECMO transport team, **early notification is paramount**. Early consultation with the ECMO team is essential, even if it is **prior to 12 hours of respiratory failure**.

## NEUROMUSCULAR BLOCKADE

If a patient has severe or rapidly worsening ARDS, a short course (48 hours) of neuromuscular blockade may facilitate continued use of Lung Protective Ventilation (LPV) while eliminating such problems as ventilator dyssynchrony.<sup>28</sup> This strategy carries a survival benefit in patients with confirmed ARDS when used early in the course of disease (within 48 hours). Cisatracurium (Nimbex<sup>®</sup>) minimizes the risk of ICU-related neuropathy or myelopathy, as compared to other neuromuscular blockers, and does not require dose adjustment in renal or hepatic insufficiency. Thus, cisatracurium is the preferred neuromuscular blocking agent in patients with ARDS.<sup>29, 30</sup>

## PRONE POSITIONING

If the patient's disease is primarily in the lower lobes (based on CXR or CT findings), a trial of prone positioning for 2–6 hours should be performed.<sup>31</sup> If the patient's gas exchange improves, continue the proning therapy. A recent study of patients with moderate to severe ARDS (P:F <150) demonstrated a mortality benefit to proning for 16 hours/day.<sup>32</sup> This is best done by an experienced team able to avoid tube/line dislodgment during the proning maneuver, and may not be practical in the deployed or austere setting. The EKG electrodes are placed on the patient's back and the eyes are taped shut. This approach is best implemented in the setting of a proning protocol which includes indications and contraindications, a pre-proning checklist, and a description of nursing care of the prone patient.

## FLUID MANAGEMENT

Patients with ARDS in the setting of a positive fluid balance have an increased mortality.<sup>33</sup> Thus, early and aggressive limitation of unnecessary volume infusion is encouraged by eliminating any "maintenance IV fluid," maximally concentrating all necessary drips, and converting IV medications to enteral. If the patient's hemodynamics can tolerate diuresis, this should be pushed aggressively.<sup>34</sup> In the setting of hemodynamic compromise, attempts should be made to minimize volume and be judicious with any trials of diuresis. Some Role 3 facilities are equipped with Continuous Renal Replacement Therapy (CRRT) which can also be used to eliminate excess intravascular volume in the setting of poor renal function under the direction of an intensivist or nephrologist experienced in this therapy (See [JTS Hyperkalemia and Dialysis in the Deployed Setting CPG<sup>35</sup>](#)). If the patient is hypoproteinemic (i.e. total protein < 6 g/dL), albumin 25 g IV every 8 hours (100 mL 25% albumin) combined with diuresis for 3-5 days has been demonstrated to improve oxygenation and diuresis in two prospective randomized studies in patients with ARDS. The goals of therapy include a CVP < 4 mmHg with evidence of effective circulation by exam (warm, no mottling and capillary refill < 2 s) and adequate urine output ( $\geq 0.5$  mL/kg/hr).<sup>12</sup>

## BLOOD PRODUCT TRANSFUSIONS

Blood products carry a risk of initiating or exacerbating respiratory failure.<sup>36-39</sup> In a recent study of the DoDTR, moderate numbers of Red Blood Cell (RBC) transfusions (2-14) increased the risk of ARDS. Furthermore, each unit of additional plasma transfused increased the risk of ARDS in intubated combat casualties by 7%.<sup>36</sup> Similar findings have also been demonstrated in the civilian trauma population.<sup>39</sup> Thus, it is imperative to balance the benefits of Damage Control Resuscitation (DCR) against the risk of ARDS. If the patient is bleeding and needs blood volume replaced, blood products should not be withheld. Furthermore, in patients with severe ARDS refractory to maximal ventilator support, transfusion of additional RBCs may be necessary to sustain adequate oxygen delivery. On the other hand, a patient who is no longer bleeding who has asymptomatic anemia<sup>40</sup> or a

mildly elevated International Normalized Ratio (INR) with a normal thromboelastogram or rotational thromboelastogram likely does not need additional blood products.

## CORTICOSTEROID ADMINISTRATION

Intravenous steroids have generally shown no benefit in the initial treatment of ARDS.<sup>41</sup> However, initiation of low to moderate-dose corticosteroids in highly-select patients can improve pulmonary mechanics and reduce ventilator and ICU days without increasing complications including infections and neuropathy/myelopathy.<sup>42,43</sup> This select population consists primarily of those with “late-phase” or “prolonged” ARDS, defined as duration of  $\geq 7$  days. The ARDSNet Late Steroid Rescue Study Trial demonstrated a potential benefit of steroids in the subgroup of patients with ARDS duration between 7-13 days, but potential harm of steroids when administered to patients who were at  $\geq 14$  days of duration. In patients without contraindications, the recommended regimen is methylprednisolone 2 mg/kg IV x1 followed by an infusion of 2 mg/kg/day (can be divided into every 6 hour doses) for 14 days (or for the duration of intubation, whichever is shorter). The infusion can then be tapered over 7-21 days based on clinical judgment. If steroids have not been initiated within two weeks of an ARDS diagnosis, they should be avoided due to an increased mortality with delayed therapy.<sup>44</sup> Of note, AEP can masquerade as ARDS and has been described in deployed military members who recently started smoking.<sup>45</sup> AEP is highly sensitive to steroid therapy; so it is very important to correctly diagnose AEP from the more common ARDS.

## NUTRITION AND VENOUS THROMBOEMBOLISM PROPHYLAXIS

Patients with ARDS receive nutritional support (See JTS [Nutritional Support Using Enteral and Parenteral Methods](#) CPG).<sup>46</sup> Enteral feeds are preferred if the gastrointestinal system is functional. Consideration should be given to positioning a naso-jejunal feeding tube for this purpose; a naso-gastric feeding tube can also be used if a feeding tube cannot be advanced through the pylorus. Stress ulcer prophylaxis is recommended in critically ill intubated patients, and all patients with ARDS should be considered for chemical Venous Thromboembolism (VTE) prophylaxis once adequate hemostasis has been achieved.

## SEDATION MANAGEMENT AND PHYSICAL THERAPY

The major long-term morbidity of ARDS is neurologic and/or musculoskeletal disability related to prolonged inactivity.<sup>29,30</sup> Consequently, at the earliest possible time, patients should undergo a daily awakening trial (“sedation holiday”)<sup>47</sup> and should be started on an aggressive program of early mobilization. This consists of a staged approach even while intubated, beginning with passive range of motion (performed multiple times daily by providers, nurses, therapists, co-workers, and family) and then progressing to sitting up at the side of the bed, moving from bed to chair, and ambulating with assistance.<sup>48,49</sup>

## ARDS IN PEDIATRIC PATIENTS

Ventilator management of ARDS in children is similar to their adult counterparts with a goal to limit ventilator-induced lung injury. Additionally, adjunctive and rescue measures are also similar in pediatric ARDS patients.<sup>16</sup>

---

## TRANSPORT OF ARDS PATIENTS

---

### CRITICAL CARE AIR TRANSPORT TEAM (CCATT) CAPABILITIES

Intubated U.S. military patients are routinely transported out of theater by the Critical Care Air Transport Team (CCATT).<sup>50-52</sup> From October 2001 to May 2006, these made up 1,265 of 1,995 (63%) of all CCATT patients.<sup>53</sup> The decision to transport a patient with ARDS should be made jointly with the theater CCATT Director and the validating flight surgeon, the on-site CCATT physician, and the Role 3 Chief of Trauma and/or ICU Director.

Considerations should include the severity of the patient's respiratory failure, the trajectory of that respiratory failure (improving or worsening), and the experience of the team.<sup>22</sup>

U.S. Air Force CCATT has both the Impact 731™ (Zoll Medical Corporation., Chelmsford, MA) ventilator and the LTV 1000™ (CareFusion., Yorba Linda, California) ventilator for use in transport.<sup>54</sup> The Impact 731 operates in volume control, pressure control, SIMV, and CPAP with and without pressure support. Up to 100% O<sub>2</sub> can be applied as can PEEP of up to 25 cm H<sub>2</sub>O. Flow rates range from 0 to 100 L/min at 40 cm H<sub>2</sub>O. Peak inspiratory pressures range from 10 to 80 cm H<sub>2</sub>O. Inverse ratio ventilation is not possible with the Impact 731.

## ADVANCED CRITICAL CARE EVACUATION TEAM (ACCET) CAPABILITIES

In 2012, SAMMC established an ECLS team and now offers long-range transport of patients with severe ARDS with or without ECLS. The team consists of a medical/pulmonary critical care physician, a surgical intensivist, an ICU nurse, and a respiratory therapist. Advanced therapies used by this team include high frequency percussive ventilator (Percussionaire VDR-4), inhaled prostacyclin (Flolan), and ECLS for the management of patients with moderate to severe ARDS who could not otherwise be safely transported.<sup>55-58</sup>

Indications for requesting an ACCET for transport to the U.S. include the following:

- PaO<sub>2</sub>: FiO<sub>2</sub> < 100 .
- Inhalation injury.
- FiO<sub>2</sub> > 0.7 or pH < 7.25 on lung-protective ventilation.
- PEEP > 15 cm H<sub>2</sub>O w/ PPLAT > 30 cm H<sub>2</sub>O.
- Severe brain injury with PaCO<sub>2</sub> > 40 mmHg on a transport ventilator.
- Cardiogenic shock refractory to maximal medical therapy.
- Anatomic derangement (e.g., Bronchopleural fistula, pneumonectomy).
- Use of advanced ventilator modes such as APRV.
- Acute Pulmonary Embolism (PE) with cardiac arrest or with persistent hypoxemia.
- Multi-system organ failure (e.g., ARDS + Renal Failure).

ACCET team members are specifically trained in the indications for and the use of these modalities which have all been appropriately vetted through the combat casualty care and transport communities.

- High-frequency percussive ventilation can be helpful in cases of purulent pneumonia or inhalation injury by mobilizing secretions while affording safe gas exchange.<sup>59</sup>
- ECLS is used for adult respiratory failure with good outcomes as demonstrated in recent series using modern equipment.<sup>60-62</sup> Most adult ECLS is Veno-Venous which can be performed through either single site internal jugular (IJ) vein cannulation, combined IJ/femoral vein (FV) or dual-FV cannulation. Systemic heparin should be administered once surgical bleeding has been controlled. This approach has been used safely in trauma patients both in the U.S. and in Germany, including patients with Traumatic Brain Injury (TBI).<sup>62-65</sup>
- ACCET transports should be initiated by the local Chief of Trauma and/or ICU Director by contacting U.S. Transportation Command (TRANSCOM) through the normal intertheater evacuation procedure. This will facilitate timely activation of the appropriate team. Physician-to-physician consultation can also be obtained by contacting LRMC at DSN 314-486-7141 or SAMMC at DSN 312-429-BURN (2876). Early consultation and ECLS team activation are always encouraged.

- From Nov 2005 – Mar 2007, 524 intubated patients were transported via CCATT. Of these, five were moved by the LRMC ALRT which had been called on a total of 11 patients. Of the five ALRT patients requiring advanced support modes, four survived to hospital discharge.<sup>66</sup> Furthermore, of 10 U.S. combat casualties transported on either Pumpless Extracorporeal Lung Assist (PECLA) or ECLS, nine survived to hospital discharge.<sup>55</sup> These data underscore the importance of utilizing available resources for transporting these tenuous patients to definitive care.

---

## OUTCOMES

---

In a general civilian population, the in-hospital mortality in patients with ARDS remains upwards of 40%<sup>67</sup> and the 5-year mortality is approximately 60%.<sup>68</sup> For trauma patients, ARDS increases morbidity<sup>69</sup> and may increase mortality as well,<sup>70</sup> although there is some inconsistency in the current civilian literature.<sup>71</sup> However, ARDS is an independent risk factor for death in combat casualties as noted above. To mitigate this risk, early LPV should be implemented along with minimizing unnecessary IV infusions, eliminating unnecessary blood product transfusions, and implementation of an aggressive physical therapy regimen if possible. Early activation of the ACCET evacuation system should also be considered.

---

## PERFORMANCE IMPROVEMENT (PI) MONITORING

---

### POPULATION OF INTEREST

All patients who receive mechanical ventilation

### INTENT (EXPECTED OUTCOMES)

1. Patients with Acute Respiratory Distress Syndrome (ARDS) are treated with lung protective ventilation.
2. Advanced airway support team consultation occurs within 4 hours when criteria are met (ex. PaO<sub>2</sub>:FiO<sub>2</sub> < 100, FiO<sub>2</sub> > 70%, PEEP > 15 cmH<sub>2</sub>O with Pplat > 30 cm H<sub>2</sub>O, severe TBI with PaCO<sub>2</sub> > 40 mmHg, etc).

### PERFORMANCE/ADHERENCE METRICS

1. Number and percentage of patients diagnosed with ARDS who receive initial tidal volume 6-8 mL/kg.
2. Number and percentage of patients who have advance airway support team consultation within 4 hours when criteria are met (ex. PaO<sub>2</sub>:FiO<sub>2</sub> < 100, FiO<sub>2</sub> > 70%, PEEP > 15 cmH<sub>2</sub>O with Pplat > 30 cm H<sub>2</sub>O, severe TBI with PaCO<sub>2</sub> > 40 mmHg, etc) and patient is eligible for evacuation (US or coalition casualties).

### DATA SOURCE

- Patient Record.
- Department of Defense Trauma Registry (DoDTR).

### SYSTEM REPORTING & FREQUENCY

The above constitutes the minimum criteria for PI monitoring of this CPG. System reporting will be performed annually; additional PI monitoring and system reporting may be performed as needed.

The system review and data analysis will be performed by the JTS Chief and JTS PI Branch.



**RESPONSIBILITIES**

It is the trauma team leader's responsibility to ensure familiarity, appropriate compliance and PI monitoring at the local level with this CPG.

---

**REFERENCES**

---


1. Edens JW, Chung KK, Pamplin JC, et al. Predictors of early acute lung injury at a combat support hospital: a prospective observational study. *J Trauma* 2010;69 Suppl 1:S81–6.
2. Rubenfeld GD, Caldwell E, Peabody E, et al. Incidence and outcomes of acute lung injury. *N Engl J Med* 2005;353(16):1685–93.
3. Eastridge BJ, Hardin M, Cantrell J, et al. Died of wounds on the battlefield: causation and implications for improving combat casualty care. *J Trauma* 2011;71(1 Suppl):S4–8.
4. Patrick Allan, Brian B. Bloom, Yolanda Barnes, et al. Combat-Associated Acute Lung Injury [Internet]. In: D16. Epidemiology of Acute Lung Injury. American Thoracic Society; 2011 [cited 2015 Jun 23]. p. A5594–A5594. Available from: [http://dx.doi.org/10.1164/ajrccm-conference.2011.183.1\\_MeetingAbstracts.A5594](http://dx.doi.org/10.1164/ajrccm-conference.2011.183.1_MeetingAbstracts.A5594)
5. Belenkiy SM, Buel AR, Cannon JW, et al. Acute respiratory distress syndrome in wartime military burns: application of the Berlin criteria. *J Trauma Acute Care Surg* 2014;76(3):821–7.
6. Park PK, Cannon JW, Wen Y, et al. Incidence and mortality of ARDS in combat casualty care. Poster presentation, Am. Assoc. Surg. Trauma. Pittsburgh, PA. 2009.
7. Park PK, Cannon JW, Ye W, et al. Transfusion strategies and development of acute respiratory distress syndrome in combat casualty care. *J Trauma Acute Care Surg* 2013;75(2 Suppl 2):S238–46.
8. Schwarz MI, Albert RK. “Imitators” of the ARDS: implications for diagnosis and treatment. *Chest* 2004;125(4):1530–5.
9. Ranieri VM, Rubenfeld GD, Thompson BT, et al. Acute respiratory distress syndrome: the Berlin definition. *JAMA* 2012;307(23):2526–33.
10. Bernard GR, Artigas A, Brigham KL, et al. The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. *Am J Respir Crit Care Med* 1994;149(3 Pt 1):818–24.
11. Duane PG, Colice GL. Impact of noninvasive studies to distinguish volume overload from ARDS in acutely ill patients with pulmonary edema: analysis of the medical literature from 1966 to 1998. *Chest* 2000;118(6):1709–17.
12. National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network, Wheeler AP, Bernard GR, et al. Pulmonary-artery versus central venous catheter to guide treatment of acute lung injury. *N Engl J Med* 2006;354(21):2213–24.
13. Dechert RE, Park PK, Bartlett RH. Evaluation of the oxygenation index in adult respiratory failure. *J Trauma Acute Care Surg* 2014;76(2):469–73.
14. Davis SL, Furman DP, Costarino AT. Adult respiratory distress syndrome in children: associated disease, clinical course, and predictors of death. *J Pediatr* 1993;123(1):35–45.
15. Khemani RG, Smith LS, Zimmerman JJ, Erickson S, Pediatric Acute Lung Injury Consensus Conference Group. Pediatric acute respiratory distress syndrome: definition, incidence, and epidemiology: proceedings from the pediatric acute lung injury consensus conference. *Pediatr Crit Care Med J Soc Crit Care Med World Fed Pediatr Intensive Crit Care Soc* 2015;16(5 Suppl 1):S23–40.

16. Pediatric Acute Lung Injury Consensus Conference Group. Pediatric acute respiratory distress syndrome: consensus recommendations from the pediatric acute lung injury consensus conference. *Pediatr Crit Care Med J Soc Crit Care Med World Fed Pediatr Intensive Crit Care Soc* 2015;16(5):428–39.
17. Slutsky AS, Ranieri VM. Ventilator-induced lung injury. *N Engl J Med* 2013;369(22):2126–36.
18. Serpa Neto A, Cardoso SO, Manetta JA, et al. Association between use of lung-protective ventilation with lower tidal volumes and clinical outcomes among patients without acute respiratory distress syndrome: a meta-analysis. *JAMA* 2012;308(16):1651–9.
19. Futier E, Constantin J-M, Paugam-Burtz C, et al. A trial of intraoperative low-tidal-volume ventilation in abdominal surgery. *N Engl J Med* 2013;369(16):428–37.
20. Petrucci N, De Feo C. Lung protective ventilation strategy for the acute respiratory distress syndrome. *Cochrane Database Syst Rev* 2013;2:CD003844.
21. Muhm JM, Rock PB, McMullin DL, et al. Effect of aircraft-cabin altitude on passenger discomfort. *N Engl J Med* 2007;357(1):18–27.
22. Mason P. CCATT Mechanical Ventilation Clinical Practice Guideline. 22 Oct 2013.
23. NHLBI ARDS Network. Ventilator Protocol Card [Internet]. [cited 2011 May 2];(May 2, 2011). Available from: <http://www.ardsnet.org/node/77791>.
24. Briel M, Meade M, Mercat A, et al. Higher vs lower positive end-expiratory pressure in patients with acute lung injury and acute respiratory distress syndrome: Systematic review and meta-analysis. *JAMA* 2010;303(9):865–73.
25. Amato MBP, Meade MO, Slutsky AS, et al. Driving Pressure and Survival in the Acute Respiratory Distress Syndrome. *N Engl J Med* 2015;372(8):747–55.
26. Diaz J V, Brower R, Calfee CS, Matthay MA. Therapeutic strategies for severe acute lung injury. *Crit Care Med* 2010;38(8):1644–50.
27. Brodie D, Bacchetta M. Extracorporeal membrane oxygenation for ARDS in adults. *N Engl J Med* 2011;365(20):1905–14.
28. Papazian L, Forel JM, Gacouin A, et al. Neuromuscular blockers in early acute respiratory distress syndrome. *N Engl J Med* 2010;363(12):1107–16.
29. Herridge MS, Tansey CM, Matte A, et al. Functional disability 5 years after acute respiratory distress syndrome. *N Engl J Med* 2011;364(14):1293–304.
30. Herridge MS, Cheung AM, Tansey CM, et al. One-year outcomes in survivors of the acute respiratory distress syndrome. *N Engl J Med* 2003;348(8):683–93.
31. Hemmila MR, Napolitano LM. Severe respiratory failure: advanced treatment options. *Crit Care Med* 2006;34(9 Suppl):S278–90.
32. Guérin C, Reignier J, Richard J-C, et al. Prone positioning in severe acute respiratory distress syndrome. *N Engl J Med* 2013;368(23):2159–68.
33. Sakr Y, Vincent JL, Reinhart K, et al. High tidal volume and positive fluid balance are associated with worse outcome in acute lung injury. *Chest* 2005;128(5):3098–108.
34. National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network, Wiedemann HP, Wheeler AP, et al. Comparison of two fluid-management strategies in acute lung injury. *N Engl J Med* 2006;354(24):2564–75.

35. Joint Trauma System, Hyperkalemia and Dialysis in the Deployed Setting CPG. 24 Jan 2017.
36. Park PK, Cannon JW, Ye W, et al. Transfusion strategies and development of ARDS in combat casualty care. *J Trauma Acute Care Surg* 2013;In press.
37. Khan H, Belsher J, Yilmaz M, et al. Fresh-frozen plasma and platelet transfusions are associated with development of acute lung injury in critically ill medical patients. *Chest* 2007;131(5):1308–14.
38. Netzer G, Shah C V, Iwashyna TJ, et al. Association of RBC transfusion with mortality in patients with acute lung injury. *Chest* 2007;132(4):1116–23.
39. Watson GA, Sperry JL, Rosengart MR, et al. Fresh frozen plasma is independently associated with a higher risk of multiple organ failure and acute respiratory distress syndrome. *J Trauma* 2009;67(2):221–30.
40. Hébert PC, Wells G, Blajchman MA, et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. *N Engl J Med* 1999;340(6):409–17.
41. Horita N, Hashimoto S, Miyazawa N, et al. Impact of Corticosteroids on Mortality in Patients with Acute Respiratory Distress Syndrome: A Systematic Review and Meta-analysis. *Intern Med Tokyo Jpn* 2015;54(12):1473–9.
42. Meduri GU, Golden E, Freire AX, et al. Methylprednisolone infusion in early severe ARDS: results of a randomized controlled trial. *Chest* 2007;131(4):954–63.
43. Tang BMP, Craig JC, Elick GD, Seppelt I, McLean AS. Use of corticosteroids in acute lung injury and acute respiratory distress syndrome: a systematic review and meta-analysis. *Crit Care Med* 2009;37(5):1594–603.
44. The National Heart, Lung and BIARDS (ARDS) CTN. Efficacy and Safety of Corticosteroids for Persistent Acute Respiratory Distress Syndrome. *N Engl J Med* 2006;354(16):1671–84.
45. Shorr AF, Scoville SL, Cersovsky SB, et al. Acute eosinophilic pneumonia among US Military personnel deployed in or near Iraq. *JAMA* 2004;292(24):2997–3005.
46. Joint Trauma System, Nutritional Support Using Enteral Parenteral Methods CPG, 04 Aug 2016.
47. Kress JP, Pohlman AS, O'Connor MF, Hall JB. Daily interruption of sedative infusions in critically ill patients undergoing mechanical ventilation. *N Engl J Med* 2000;342(20):1471–7.
48. Pohlman MC, Schweickert WD, Pohlman AS, et al. Feasibility of physical and occupational therapy beginning from initiation of mechanical ventilation. *Crit Care Med* 2010;38(11):2089–94.
49. Schweickert WD, Pohlman MC, Pohlman AS, et al. Early physical and occupational therapy in mechanically ventilated, critically ill patients: a randomised controlled trial. *Lancet* 2009;373(9678):1874–82.
50. Beninati W, Meyer MT, Carter TE. The critical care air transport program. *Crit Care Med* 2008;36(7 Suppl):S370–6.
51. Mason PE, Eadie JS, Holder AD. Prospective observational study of United States (US) Air Force Critical Care Air Transport team operations in Iraq. *J Emerg Med* 2011;41(1):8–13.
52. Ingalls N, Zonies D, Bailey JA, et al. A review of the first 10 years of critical care aeromedical transport during operation iraqi freedom and operation enduring freedom: the importance of evacuation timing. *JAMA Surg* 2014;149(8):807–13.
53. Bridges E, Evers K. Wartime critical care air transport. *Mil Med* 2009;174(4):370–5.
54. Rodriguez Jr. D, Blakeman TC, Dorlac W, Johannigman JA, Branson RD. Maximizing oxygen delivery during mechanical ventilation with a portable oxygen concentrator. *J Trauma* 2010;69 Suppl 1:S87-93.

55. Bein T, Zonies D, Philipp A, et al. Transportable extracorporeal lung support for rescue of severe respiratory failure in combat casualties. *J Trauma Acute Care Surg* 2012;73(6):1450–6.
56. Allan PF, Osborn EC, Bloom BB, Wanek S, Cannon JW. The introduction of extracorporeal membrane oxygenation to aeromedical evacuation. *Mil Med* 2011;176(8):932–7.
57. Cannon JW, Zonies DH, Benfield RJ, Elster EA, Wanek SM. Advanced en-route critical care during combat operations. *Bull Am Coll Surg* 2011;96(5):21–9.
58. Zimmermann M, Philipp A, Schmid FX, Dorlac W, Arlt M, Bein T. From Baghdad to Germany: use of a new pumpless extracorporeal lung assist system in two severely injured US soldiers. *ASAIO J* 2007;53(3):e4–6.
59. Chung KK, Wolf SE, Renz EM, et al. High-frequency percussive ventilation and low tidal volume ventilation in burns: a randomized controlled trial. *Crit Care Med* 2010;38(10):1970–7.
60. Peek GJ, Mugford M, Tiruvoipati R, et al. Efficacy and economic assessment of conventional ventilatory support versus extracorporeal membrane oxygenation for severe adult respiratory failure (CESAR): a multicentre randomised controlled trial. *Lancet* 2009;374(9698):1351–63.
61. Davies A, Jones D, Bailey M, et al. Extracorporeal Membrane Oxygenation for 2009 Influenza A(H1N1) Acute Respiratory Distress Syndrome. *JAMA* 2009;302(17):1888–95.
62. Guirand DM, Okoye OT, Schmidt BS, et al. Venovenous extracorporeal life support improves survival in adult trauma patients with acute hypoxemic respiratory failure: a multicenter retrospective cohort study. *J Trauma Acute Care Surg* 2014;76(5):1275–81.
63. Arlt M, Philipp A, Voelkel S, et al. Extracorporeal membrane oxygenation in severe trauma patients with bleeding shock. *Resuscitation* 2010;81(7):804–9.
64. Michaels AJ, Schriener RJ, Kolla S, et al. Extracorporeal life support in pulmonary failure after trauma. *J Trauma* 1999;46(4):638–45.
65. Muellenbach RM, Kredel M, Kunze E, et al. Prolonged heparin-free extracorporeal membrane oxygenation in multiple injured acute respiratory distress syndrome patients with traumatic brain injury. *J Trauma Acute Care Surg* 2012;72(5):1444–7.
66. Dorlac GR, Fang R, Pruitt VM, et al. Air transport of patients with severe lung injury: development and utilization of the Acute Lung Rescue Team. *J Trauma* 2009;66(4 Suppl):S164–71.
67. Rubenfeld GD, Herridge MS. Epidemiology and outcomes of acute lung injury. *Chest* 2007;131(2):554–62.
68. Herridge MS, Tansey CM, Matte A, et al. Functional disability 5 years after acute respiratory distress syndrome. *N Engl J Med* 2011;364(14):1293–304.
69. Salim A, Martin M, Constantinou C, et al. Acute respiratory distress syndrome in the trauma intensive care unit: morbid but not mortal. *Arch Surg* 2006;141(7):655–8.
70. Shah CV, Localio AR, Lanken PN, et al. The impact of development of acute lung injury on hospital mortality in critically ill trauma patients. *Crit Care Med* 2008;36(8):2309–15.
71. Treggiari MM, Hudson LD, Martin DP, Weiss NS, Caldwell E, Rubenfeld G. Effect of acute lung injury and acute respiratory distress syndrome on outcome in critically ill trauma patients. *Crit Care Med* 2004;32(2):327–31.

APPENDIX A: DIAGNOSIS AND MANAGEMENT OF ARDS



APPENDIX B: ARDSNET VENTILATOR MANAGEMENT FOR PATIENTS WITH ARDS<sup>23</sup>



NIH NHLBI ARDS Clinical Network  
Mechanical Ventilation Protocol Summary

**INCLUSION CRITERIA: Acute onset of**

1. PaO<sub>2</sub>/FiO<sub>2</sub> ≤ 300 (corrected for altitude)
2. Bilateral (patchy, diffuse, or homogeneous) infiltrates consistent with pulmonary edema
3. No clinical evidence of left atrial hypertension

**PART I: VENTILATOR SETUP AND ADJUSTMENT**

1. Calculate predicted body weight (PBW)  
**Males** = 50 + 2.3 [height (inches) - 60]  
**Females** = 45.5 + 2.3 [height (inches) - 60]
2. Select any ventilator mode
3. Set ventilator settings to achieve initial V<sub>T</sub> = 8 ml/kg PBW
4. Reduce V<sub>T</sub> by 1 ml/kg at intervals ≤ 2 hours until V<sub>T</sub> = 6ml/kg PBW.
5. Set initial rate to approximate baseline minute ventilation (not > 35 bpm).
6. Adjust V<sub>T</sub> and RR to achieve pH and plateau pressure goals below.

**OXYGENATION GOAL: PaO<sub>2</sub> 55-80 mmHg or SpO<sub>2</sub> 88-95%**

Use a minimum PEEP of 5 cm H<sub>2</sub>O. Consider use of incremental FiO<sub>2</sub>/PEEP combinations such as shown below (not required) to achieve goal.

**Lower PEEP/higher FiO<sub>2</sub>**

FiO <sub>2</sub>	0.3	0.4	0.4	0.5	0.5	0.6	0.7	0.7
PEEP	5	5	8	8	10	10	10	12

FiO <sub>2</sub>	0.7	0.8	0.9	0.9	0.9	1.0
PEEP	14	14	14	16	18	18-24

**Higher PEEP/lower FiO<sub>2</sub>**

FiO <sub>2</sub>	0.3	0.3	0.3	0.3	0.3	0.4	0.4	0.5
PEEP	5	8	10	12	14	14	16	16

FiO <sub>2</sub>	0.5	0.5-0.8	0.8	0.9	1.0	1.0
PEEP	18	20	22	22	22	24

**PLATEAU PRESSURE GOAL: ≤ 30 cm H<sub>2</sub>O**

Check Pplat (0.5 second inspiratory pause), at least q 4h and after each change in PEEP or V<sub>T</sub>.

**If Pplat > 30 cm H<sub>2</sub>O:** decrease V<sub>T</sub> by 1ml/kg steps (minimum = 4 ml/kg).

**If Pplat < 25 cm H<sub>2</sub>O and V<sub>T</sub> < 6 ml/kg,** increase V<sub>T</sub> by 1 ml/kg until Pplat > 25 cm H<sub>2</sub>O or V<sub>T</sub> = 6 ml/kg.

**If Pplat < 30 and breath stacking or dys-synchrony occurs:** may increase V<sub>T</sub> in 1ml/kg increments to 7 or 8 ml/kg if Pplat remains ≤ 30 cm H<sub>2</sub>O.

**pH GOAL: 7.30-7.45**

**Acidosis Management: (pH < 7.30)**

**If pH 7.15-7.30:** Increase RR until pH > 7.30 or PaCO<sub>2</sub> < 25 (Maximum set RR = 35).

**If pH < 7.15:** Increase RR to 35.

If pH remains < 7.15, V<sub>T</sub> may be increased in 1 ml/kg steps until pH > 7.15 (Pplat target of 30 may be exceeded).  
May give NaHCO<sub>3</sub>

**Alkalosis Management: (pH > 7.45)** Decrease vent rate if possible.

**I: E RATIO GOAL:** Recommend that duration of inspiration be ≤ duration of expiration.

**PART II: WEANING**

**A. Conduct a SPONTANEOUS BREATHING TRIAL daily when:**

1. FiO<sub>2</sub> ≤ 0.40 and PEEP ≤ 8 OR FiO<sub>2</sub> ≤ 0.50 and PEEP ≤ 5.
2. PEEP and FiO<sub>2</sub> ≤ values of previous day.
3. Patient has acceptable spontaneous breathing efforts. (May decrease vent rate by 50% for 5 minutes to detect effort.)
4. Systolic BP ≥ 90 mmHg without vasopressor support.
5. No neuromuscular blocking agents or blockade.

**B. SPONTANEOUS BREATHING TRIAL (SBT):**

**If all above criteria are met and subject has been in the study for at least 12 hours, initiate a trial of UP TO 120 minutes of spontaneous breathing with FiO<sub>2</sub> ≤ 0.5 and PEEP ≤ 5:**

1. Place on T-piece, trach collar, or CPAP ≤ 5 cm H<sub>2</sub>O with PS ≤ 5
2. Assess for tolerance as below for up to two hours.
  - a. SpO<sub>2</sub> ≥ 90: and/or PaO<sub>2</sub> ≥ 60 mmHg
  - b. Spontaneous V<sub>T</sub> ≥ 4 ml/kg PBW
  - c. RR ≤ 35/min
  - d. pH ≥ 7.3
  - e. No respiratory distress (distress= 2 or more)
    - HR > 120% of baseline
    - Marked accessory muscle use
    - Abdominal paradox
    - Diaphoresis
    - Marked dyspnea
3. If tolerated for at least 30 minutes, consider extubation.
4. If not tolerated resume pre-weaning settings.

**Definition of UNASSISTED BREATHING  
(Different from the spontaneous breathing criteria as PS is not allowed)**

1. Extubated with face mask, nasal prong oxygen, or room air, OR
2. T-tube breathing, OR
3. Tracheostomy mask breathing, OR
4. CPAP less than or equal to 5 cm H<sub>2</sub>O without pressure support or IMV assistance.

---

**APPENDIX C: PRONE POSITIONING IN PATIENTS WITH ARDS**

---

**PREPARATION:**

1. Check for contraindications.
  - Facial or pelvic fractures
  - Anterior torso wounds or burns
  - Spinal instability
  - Increased ICP
2. Confirm ETT placement with recent CXR.
3. Ensure that ETT and all invasive lines/monitors (chest tubes, IVs, central lines) are secured.
4. Consider how patient's head, neck, shoulder girdle will be supported.
5. Stop tube feedings, evacuate stomach, cap/clamp feeding and gastric tubes.
6. Prepare airway suctioning equipment.
7. Prepare all IV tubing, catheters, etc., for prone connections.
  - Assure sufficient tubing length
  - Relocate drainage bags to opposite side of bed
  - Move chest tube drains to between legs
  - Reposition IV tubing to patient's head on opposite side of bed

**TURNING**

1. Place personnel on both sides and head of bed.
2. Increase FiO<sub>2</sub> to 1.0, and note TV, minute ventilation, peak/plateau pressures.
3. Place new draw sheet, put patient into lateral decubitus position.
4. Remove EKG leads and patches. Suction airway, oropharynx, nares as necessary.
5. Continue to proning, and reposition patient in center of bed.
6. Turn patient's face toward ventilator. Ensure airway is not kinked and has not migrated.
7. Support face/shoulders appropriately; ensure no contact of padding with eyes/orbits.
8. Position patient's arms for comfort. Avoid arm extension that might cause brachial plexopathy.
9. Auscultate chest for mainstem intubation; reassess TV and minute ventilation.
10. Reconnect and adjust all tubing, check functions.
11. Reattach ECG patches and leads to back.
12. Tilt patient in reverse Trendelenburg. Intermittent slight (200) lateral repositioning every two hours, if possible.
13. Document skin assessment on weight-bearing surfaces every shift.

---

**APPENDIX D: ADDITIONAL INFORMATION REGARDING OFF-LABEL USES IN CPGS**

---

**PURPOSE**

The purpose of this Appendix is to ensure an understanding of DoD policy and practice regarding inclusion in CPGs of “off-label” uses of U.S. Food and Drug Administration (FDA)–approved products. This applies to off-label uses with patients who are armed forces members.

**BACKGROUND**

Unapproved (i.e., “off-label”) uses of FDA-approved products are extremely common in American medicine and are usually not subject to any special regulations. However, under Federal law, in some circumstances, unapproved uses of approved drugs are subject to FDA regulations governing “investigational new drugs.” These circumstances include such uses as part of clinical trials, and in the military context, command required, unapproved uses. Some command requested unapproved uses may also be subject to special regulations.

**ADDITIONAL INFORMATION REGARDING OFF-LABEL USES IN CPGS**

The inclusion in CPGs of off-label uses is not a clinical trial, nor is it a command request or requirement. Further, it does not imply that the Military Health System requires that use by DoD health care practitioners or considers it to be the “standard of care.” Rather, the inclusion in CPGs of off-label uses is to inform the clinical judgment of the responsible health care practitioner by providing information regarding potential risks and benefits of treatment alternatives. The decision is for the clinical judgment of the responsible health care practitioner within the practitioner-patient relationship.

**ADDITIONAL PROCEDURES****Balanced Discussion**

Consistent with this purpose, CPG discussions of off-label uses specifically state that they are uses not approved by the FDA. Further, such discussions are balanced in the presentation of appropriate clinical study data, including any such data that suggest caution in the use of the product and specifically including any FDA-issued warnings.

**Quality Assurance Monitoring**

With respect to such off-label uses, DoD procedure is to maintain a regular system of quality assurance monitoring of outcomes and known potential adverse events. For this reason, the importance of accurate clinical records is underscored.

**Information to Patients**

Good clinical practice includes the provision of appropriate information to patients. Each CPG discussing an unusual off-label use will address the issue of information to patients. When practicable, consideration will be given to including in an appendix an appropriate information sheet for distribution to patients, whether before or after use of the product. Information to patients should address in plain language: a) that the use is not approved by the FDA; b) the reasons why a DoD health care practitioner would decide to use the product for this purpose; and c) the potential risks associated with such use.